ABSTRACT
The last malaria cases in near-elimination settings are often found in international border regions due to the presence of hard-to-reach populations, conflict, uneven intervention coverage, and human migration. Test-and-treat border posts are an under-researched form of active case detection used to interrupt transmission chains between countries. We used an individual-based, mathematical metapopulation model of P. falciparum to estimate the effectiveness of border posts on total cases in malaria-endemic sub-Saharan Africa. We estimated that implementation of international border posts across 401 sub-national administrative units would avert a median of 7,173 (IQR: 1,075 to 23,550) cases per unit over a 10-year period and reduce PfPR2-10 by a median of 0.21% (IQR: 0.04% to 0.44%). Border posts were most effective in low-transmission settings with high-transmission neighbors. Border posts alone will not allow a country to reach elimination, particularly when considering feasibility and acceptability, but could contribute to broader control packages to targeted populations.
Competing Interest Statement
KH has received personal fees from WHO, Pfizer, and GSK for work unrelated to this paper. All other authors declare that they have no competing interests.
Funding Statement
This work was supported by the Wellcome Trust [reference 220900/Z/20/Z]. HMT, GDC, NS, MP, KH, and ACG acknowledge funding from the MRC Centre for Global Infectious Disease Analysis (reference MR/X020258/1), funded by the UK Medical Research Council (MRC). This UK funded award is carried out in the frame of the Global Health EDCTP3 Joint Undertaking. KH is additionally funded by the National Institute for Health and Care Research (NIHR) Health Protection Research Unit in Modelling and Health Economics, a partnership between the UK Health Security Agency, Imperial College London and LSHTM [grant code NIHR200908]. KH also acknowledges funding from Community Jameel and by Kenneth C. Griffin. Disclaimer: ″The views expressed are those of the author(s) and not necessarily those of the NIHR, UK Health Security Agency or the Department of Health and Social Care.″
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The data required to fit duration estimates for mixing matrices can be found in Marshall et al. 2016. Unit parameters for epidemiological data, population size, historical intervention coverage, mosquito vectors, and seasonality were obtained from publicly available resources referenced in the methods section. Full analysis code, including model parameterization, unit parameterization, and mixing algorithms are provided at: https://github.com/htopazian/border_elimination.
